Breaking News

Mpox Vaccination Found Effective

March 14, 2023 • 4:15 am CDT
by Kevin Phillips
(Precision Vaccinations)

A recent Lancet Lancet Infectious Diseases analysis concluded that a single dose of Modified Vaccinia Ankara (MVA-BN, Jynneos®) vaccine was very protective against mpox.

Published on March 13, 2023, Dimie Ogoina, with Niger Delta University and colleagues, wrote the 78% vaccine effectiveness reported suggests that a single dose of Jynneos is considered protective against symptomatic mpox only after 13 days post-vaccination.

Furthermore, this analysis and other studies suggest that using a single dose of Bavarian Nordic's Jynneos as pre-exposure prophylaxis is preferable to post-exposure prophylaxis to guarantee protection against symptomatic mpox.

And because people living with HIV have been shown to have a higher risk of breakthrough COVID-19 infections post-vaccination, identifying four of eight breakthrough mpox infections among people living with HIV is noteworthy.

However, the Jynneos vaccine has previously been shown to be immunogenic among adults with a history of AIDS.

Since there are no approved HIV vaccines, co-administration data is unavailable.

Additional Mpox outbreak news is posted at MpoxToday.